H.I.G. Capital Completes the Sale of BIOVECTRA

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $65 billion of capital under management, is pleased to announce the sale of its portfolio company, BIOVECTRA Inc. (“BIOVECTRA” or the “Company”), a leading contract development and manufacturing organization (CDMO) of active pharmaceutical ingredients and intermediates, to Agilent Technologies, Inc. (NYSE: A) for a purchase price of $925 million. Headquartered in Charlottetown, Prince Edward Island, Canada, BIOVECTRA has approximately 650 employees and eight facilities with over 270,000 square feet of facility space. The Company produces biologics, highly potent active pharmaceutical ingredients, and other molecules for targeted therapeutics.

Read the full article: H.I.G. Capital Completes the Sale of BIOVECTRA //

Source: https://www.businesswire.com/news/home/20240923272694/en/H.I.G.-Capital-Completes-the-Sale-of-BIOVECTRA

Scroll to Top